{"id":{"repo_id":"cape-town","oai_identifier":"oai:open.uct.ac.za:11427/36776"},"canonical_url":"https://search.dev.ndltd.org/etd/cape-town/oai:open.uct.ac.za:11427/36776","repository":{"repo_id":"cape-town","name":"University of Cape Town","base_url":"https://open.uct.ac.za/oai/request"},"display":{"title":"Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations","abstract":"The global scale-up of tuberculosis treatment administered with antiretroviral therapy (ART) is the primary contributor to the 11 million averted deaths among individuals living with HIV observed between 2000 and 2019 in adults and children. Unfortunately, not all patients in need could fully benefit from these recent improvements in treatment because neglected populations are often excluded from clinical trials, including pregnant and breastfeeding women, children, adolescents, those with co-morbidities requiring additional drug treatments, and those with drug-resistant strains. This leaves many unanswered questions surrounding the management of TB, HIV, and TB/HIV in these vulnerable subpopulations. In this thesis, we utilise population pharmacokinetics and pharmacodynamic modelling to improve TB and HIV treatment in neglected populations using data from patients with TB or/and HIV. We analyse the pharmacogenomics, pharmacokinetics, and drug-drug interaction of efavirenz, isoniazid, and bedaquiline in pregnant women and characterise the pharmacokinetics and pharmacodynamics of high dose isoniazid in adults with multidrugresistant tuberculosis. We found that isoniazid and efavirenz exposures were reduced during pregnancy, but the main determinants of drug concentration were N-acetyltransferase 2 and CYP2B6 genotypes, which resulted in a 5-fold difference for both drugs between rapid and slow metabolisers. Bedaquiline exposures were lower during both postpartum and antepartum compared to historical data in non-pregnant patients. For high dose isoniazid, we observed markedly lower isoniazid exposures in participants on combination MDR-TB treatment compared to monotherapy and identified saturable kinetics at doses >10 mg/kg. We suggest that dosing isoniazid based on N-acetyltransferase 2 acetylator status might help patients attain effective exposures against inhA-mutated isolates.","abstract_html":"The global scale-up of tuberculosis treatment administered with antiretroviral therapy (ART) is the primary contributor to the 11 million averted deaths among individuals living with HIV observed between 2000 and 2019 in adults and children. Unfortunately, not all patients in need could fully benefit from these recent improvements in treatment because neglected populations are often excluded from clinical trials, including pregnant and breastfeeding women, children, adolescents, those with co-morbidities requiring additional drug treatments, and those with drug-resistant strains. This leaves many unanswered questions surrounding the management of TB, HIV, and TB/HIV in these vulnerable subpopulations. In this thesis, we utilise population pharmacokinetics and pharmacodynamic modelling to improve TB and HIV treatment in neglected populations using data from patients with TB or/and HIV. We analyse the pharmacogenomics, pharmacokinetics, and drug-drug interaction of efavirenz, isoniazid, and bedaquiline in pregnant women and characterise the pharmacokinetics and pharmacodynamics of high dose isoniazid in adults with multidrugresistant tuberculosis. We found that isoniazid and efavirenz exposures were reduced during pregnancy, but the main determinants of drug concentration were N-acetyltransferase 2 and CYP2B6 genotypes, which resulted in a 5-fold difference for both drugs between rapid and slow metabolisers. Bedaquiline exposures were lower during both postpartum and antepartum compared to historical data in non-pregnant patients. For high dose isoniazid, we observed markedly lower isoniazid exposures in participants on combination MDR-TB treatment compared to monotherapy and identified saturable kinetics at doses >10 mg/kg. We suggest that dosing isoniazid based on N-acetyltransferase 2 acetylator status might help patients attain effective exposures against inhA-mutated isolates.","abstract_has_math":false,"creators":["Gausi, Kamunkhwala"],"institution":"Department of Medicine","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Denti, Paolo"],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022","date_published":"2022","updated_at":"2026-07-22T22:22:55Z","subjects":["Clinical Pharmacology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11427/36776","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Denti, Paolo"]},{"key":"dc:creator","label":"Author","values":["Gausi, Kamunkhwala"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2022-08-30T10:06:37Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2022-08-30T10:06:37Z"]},{"key":"dc:date.issued","label":"Date","values":["2022"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Department of Medicine"]},{"key":"dc:type","label":"Dc Type","values":["Doctoral Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral","PhD"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Clinical Pharmacology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11427/36776"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The global scale-up of tuberculosis treatment administered with antiretroviral therapy (ART) is the primary contributor to the 11 million averted deaths among individuals living with HIV observed between 2000 and 2019 in adults and children. Unfortunately, not all patients in need could fully benefit from these recent improvements in treatment because neglected populations are often excluded from clinical trials, including pregnant and breastfeeding women, children, adolescents, those with co-morbidities requiring additional drug treatments, and those with drug-resistant strains. This leaves many unanswered questions surrounding the management of TB, HIV, and TB/HIV in these vulnerable subpopulations. In this thesis, we utilise population pharmacokinetics and pharmacodynamic modelling to improve TB and HIV treatment in neglected populations using data from patients with TB or/and HIV. We analyse the pharmacogenomics, pharmacokinetics, and drug-drug interaction of efavirenz, isoniazid, and bedaquiline in pregnant women and characterise the pharmacokinetics and pharmacodynamics of high dose isoniazid in adults with multidrugresistant tuberculosis. We found that isoniazid and efavirenz exposures were reduced during pregnancy, but the main determinants of drug concentration were N-acetyltransferase 2 and CYP2B6 genotypes, which resulted in a 5-fold difference for both drugs between rapid and slow metabolisers. Bedaquiline exposures were lower during both postpartum and antepartum compared to historical data in non-pregnant patients. For high dose isoniazid, we observed markedly lower isoniazid exposures in participants on combination MDR-TB treatment compared to monotherapy and identified saturable kinetics at doses >10 mg/kg. We suggest that dosing isoniazid based on N-acetyltransferase 2 acetylator status might help patients attain effective exposures against inhA-mutated isolates."]},{"key":"dc:title","label":"Title","values":["Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations"]}]}],"canonical_facts":{"dc:contributor.advisor":["Denti, Paolo"],"dc:creator":["Gausi, Kamunkhwala"],"dc:date.accessioned":["2022-08-30T10:06:37Z"],"dc:date.available":["2022-08-30T10:06:37Z"],"dc:date.issued":["2022"],"dc:description.abstract":["The global scale-up of tuberculosis treatment administered with antiretroviral therapy (ART) is the primary contributor to the 11 million averted deaths among individuals living with HIV observed between 2000 and 2019 in adults and children. Unfortunately, not all patients in need could fully benefit from these recent improvements in treatment because neglected populations are often excluded from clinical trials, including pregnant and breastfeeding women, children, adolescents, those with co-morbidities requiring additional drug treatments, and those with drug-resistant strains. This leaves many unanswered questions surrounding the management of TB, HIV, and TB/HIV in these vulnerable subpopulations. In this thesis, we utilise population pharmacokinetics and pharmacodynamic modelling to improve TB and HIV treatment in neglected populations using data from patients with TB or/and HIV. We analyse the pharmacogenomics, pharmacokinetics, and drug-drug interaction of efavirenz, isoniazid, and bedaquiline in pregnant women and characterise the pharmacokinetics and pharmacodynamics of high dose isoniazid in adults with multidrugresistant tuberculosis. We found that isoniazid and efavirenz exposures were reduced during pregnancy, but the main determinants of drug concentration were N-acetyltransferase 2 and CYP2B6 genotypes, which resulted in a 5-fold difference for both drugs between rapid and slow metabolisers. Bedaquiline exposures were lower during both postpartum and antepartum compared to historical data in non-pregnant patients. For high dose isoniazid, we observed markedly lower isoniazid exposures in participants on combination MDR-TB treatment compared to monotherapy and identified saturable kinetics at doses >10 mg/kg. We suggest that dosing isoniazid based on N-acetyltransferase 2 acetylator status might help patients attain effective exposures against inhA-mutated isolates."],"dc:identifier.uri":["http://hdl.handle.net/11427/36776"],"dc:publisher.department":["Department of Medicine"],"dc:subject":["Clinical Pharmacology"],"dc:title":["Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations"],"dc:type":["Doctoral Thesis"],"dc:type.qualificationlevel":["Doctoral","PhD"]},"updated_at":"2026-07-22T22:22:55Z"}